The stock of Moderna Inc. (NASDAQ:MRNA) increased by $2.16 on Tuesday to finish at $115.99, up 1.90 percent. The last five days have seen an average of 2,949,000 shares of common stock traded. 6 times new highs were reached in the current year, with a fall of -$63.63. The average number of shares traded over the last 20 days was 4,601,285, while the average volume over the last 50 days totaled 3,744,098.
MRNA stock dropped -1.42% since last month. On 08/16/23, the company’s shares reached a one-month low of $95.02. The stock touched a high of $217.25 on 01/18/23, after rallying from a low of $95.02 in 52 weeks. The price of MRNA stock has declined by -35.42% or -$63.63 this year, reaching a new high 6 times. Still, the stock price is down -46.61% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
MRNA stock investors should be aware that Moderna Inc. (MRNA) stock had its last reported insider trading activity 7 days ago on Aug 23. On Aug 23, Director AFEYAN NOUBAR sold 15,000 shares at $115.51 each. This transaction resulted in the insider making $1,732,613. On Aug 17, Hoge Stephen sold 15,000 shares at a price of US$100.00. After the transaction, the insider now owns 1,587,579 shares. Director AFEYAN NOUBAR had earlier sold 10,000 shares on Aug 16 for $97.56 a share. The transaction was completed for $975,614.
Valuation Metrics
Moderna Inc. (MRNA) has a trailing price-to-earnings (P/E) ratio of 42.90. Beta for the stock is 1.62. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 4.17, the price-to-book (PB) ratio of 2.61.
Financial Health
For the recent quarter, Moderna Inc.’s quick ratio was 3.20, while its current ratio was 3.40, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the recent quarter is 0.05, and the total debt to equity ratio is 0.06. As far as profitability goes, gross margin for the trailing twelve months is 57.40% percent. Moderna Inc.’s EBITDA margin for the recent year was 50.31%, whereas its operating margin stood at 4.80% for the same period. Based on annual data, it had gross profit of $13.85 billion and revenue of $19.26 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. MRNA’s return on assets (ROA) during the last 12 months has been 4.90%. There was a 40.60% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 6.60%.
Earnings Surprise
A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $344.0 million, while revenues fell by -1280.52% to $1.86 billion. EBITDA was -$1.79 billion for the quarter. At the end of Moderna Inc.’s most recent quarter, its liabilities totaled 4.93 billion, while its total debt was $1.17 billion. Equity owned by shareholders amounts to $380.59 million.
Technical Picture
Here’s a quick look at Moderna Inc.’s (MRNA) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 61.77%, suggesting the stock is Neutral, with a 64.43% historical volatility rate.
The stochastic %K and %D were 83.39% and 80.92% respectively, while the average true range (ATR) was 4.88. Based on the 14-day stochastic reading of 92.54%, the RSI (14) reading is 56.21%. On the 9-day MACD Oscillator, the stock is at 2.25, and the 14-day reading is at 6.62.
Analyst Ratings
Moderna Inc. (NASDAQ: MRNA) was downgraded by TD Cowen to a a Market perform rating in its latest research report. The stock was previously rated as a an Outperform. Analysts have assigned Moderna Inc. (MRNA) an Overweight rating. MRNA is a stock that is recommended for selling by 2 brokerage firms, while 10 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 2 rates it overweight and 8 others recommend it as a buy.
What is MRNA’s price target for the next 12 months?
The current consensus forecast for the stock is between $68.00 and $430.00, with a median target price of $167.00. In analyzing these forecasts, the average price target given by analysts for Moderna Inc. (MRNA) is $180.21.
